Logo image of GLSI

GREENWICH LIFESCIENCES INC (GLSI) Stock Fundamental Analysis

NASDAQ:GLSI - Nasdaq - US3968791083 - Common Stock - Currency: USD

11.57  +0.08 (+0.7%)

After market: 11.57 0 (0%)

Fundamental Rating

2

GLSI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. The financial health of GLSI is average, but there are quite some concerns on its profitability. GLSI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GLSI has reported negative net income.
In the past year GLSI has reported a negative cash flow from operations.
GLSI had negative earnings in each of the past 5 years.
GLSI had a negative operating cash flow in each of the past 5 years.
GLSI Yearly Net Income VS EBIT VS OCF VS FCFGLSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

GLSI has a worse Return On Assets (-602.52%) than 96.76% of its industry peers.
Looking at the Return On Equity, with a value of -1262.97%, GLSI is doing worse than 82.37% of the companies in the same industry.
Industry RankSector Rank
ROA -602.52%
ROE -1262.97%
ROIC N/A
ROA(3y)-190.29%
ROA(5y)-118.83%
ROE(3y)-271.69%
ROE(5y)-167.76%
ROIC(3y)N/A
ROIC(5y)N/A
GLSI Yearly ROA, ROE, ROICGLSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GLSI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLSI Yearly Profit, Operating, Gross MarginsGLSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, GLSI has more shares outstanding
Compared to 5 years ago, GLSI has more shares outstanding
GLSI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLSI Yearly Shares OutstandingGLSI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
GLSI Yearly Total Debt VS Total AssetsGLSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

An Altman-Z score of 9.66 indicates that GLSI is not in any danger for bankruptcy at the moment.
GLSI has a better Altman-Z score (9.66) than 85.97% of its industry peers.
GLSI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.66
ROIC/WACCN/A
WACCN/A
GLSI Yearly LT Debt VS Equity VS FCFGLSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 1.91 indicates that GLSI should not have too much problems paying its short term obligations.
GLSI's Current ratio of 1.91 is on the low side compared to the rest of the industry. GLSI is outperformed by 77.16% of its industry peers.
A Quick Ratio of 1.91 indicates that GLSI should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.91, GLSI is not doing good in the industry: 75.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.91
Quick Ratio 1.91
GLSI Yearly Current Assets VS Current LiabilitesGLSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for GLSI have decreased strongly by -74.08% in the last year.
EPS 1Y (TTM)-74.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.1%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GLSI Yearly EPS VS EstimatesGLSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GLSI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GLSI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GLSI Price Earnings VS Forward Price EarningsGLSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GLSI Per share dataGLSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GLSI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GREENWICH LIFESCIENCES INC

NASDAQ:GLSI (7/25/2025, 8:00:01 PM)

After market: 11.57 0 (0%)

11.57

+0.08 (+0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-20 2025-05-20/amc
Earnings (Next)08-12 2025-08-12
Inst Owners9.47%
Inst Owner Change-0.1%
Ins Owners54.28%
Ins Owner Change0.25%
Market Cap154.69M
Analysts82.86
Price Target39.78 (243.82%)
Short Float %16.8%
Short Ratio25.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-93.45%
Min EPS beat(2)-184.78%
Max EPS beat(2)-2.12%
EPS beat(4)2
Avg EPS beat(4)-44.58%
Min EPS beat(4)-184.78%
Max EPS beat(4)6.63%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 117.88
P/tB 117.96
EV/EBITDA N/A
EPS(TTM)-1.26
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -602.52%
ROE -1262.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-190.29%
ROA(5y)-118.83%
ROE(3y)-271.69%
ROE(5y)-167.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.91
Quick Ratio 1.91
Altman-Z 9.66
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y20.1%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-74.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.96%
OCF growth 3YN/A
OCF growth 5YN/A